Clinical and laboratory changes produced by piroxicam in rheumatoid arthritis.
Twenty-five patients with active rheumatoid arthritis received treatment with piroxicam during 12 weeks in an open, non-comparative trial. In addition to improvement of clinical parameters, a significant diminution of the erythrocyte sedimentation rate and a decrease in rheumatoid factor titers was noted in both serum and synovial fluid.